BNP Paribas Issuance (P16YT9) News

Helix Exploration PLC CEO Bo Sears talked with Proactive's Stephen Gunnion about the company’s development progress at its Rudyard project in Montana. Sears said the company is “progressing nicely” with the Linda #1 well and is on track to begin producing helium by the end of summer. He pointed to strong early results from both Darwin #1 and the acquisition of the Weil #1 well, expressing optimism about long-term production capacity. He described Rudyard as “quite large relative to our peers,” adding that it may support up to 20 wells—substantially more than originally anticipated. This scale opens the potential for on-site helium liquefaction, with HeLIX already acquiring 20 acres in preparation. Sears referenced a 1977 US Bureau of Mines study that estimated the field's potential at 2.60 billion cubic feet of helium. With new drilling data, including from Linda #1 and re-perforated Weil #1, the company expects to significantly update resource estimates. The company anticipates up to 4 billion cubic feet of recoverable helium, which Sears noted could make Helix one of the largest helium producers in the US. Sears also confirmed ongoing discussions with off-takers and potential interest in geological hydrogen from deeper zones. Visit Proactive’s YouTube channel for more interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #HeLIXExploration #HeliumProduction #NaturalGas #RudyardField #BoSears #MontanaEnergy #EnergyExploration #HydrogenExploration #ProactiveInvestors #USHeliumMarket

First Phosphate Corp. CEO John Passalacqua joined Steve Darling from Proactive to outline the company’s pivotal mission: powering the resurgence of American manufacturing by supplying domestically sourced Lithium Iron Phosphate (LFP) battery materials essential to factory automation, robotics, and energy storage systems. Passalacqua emphasized that the future of U.S. manufacturing is closely tied to the widespread adoption of industrial automation and robotics—technologies that rely heavily on LFP batteries. Known for their safety, longevity, and scalability, LFP batteries are rapidly becoming the global standard for grid-scale storage and automated production systems. This shift is being accelerated by evolving national trade and security policies aimed at strengthening domestic capabilities and reducing dependence on foreign supply chains. According to First Phosphate, the demand for industrial automation is expected to soar to USD $307.7 billion by 2030. With around 60% of jobs poised to automate at least 30% of tasks, automation could boost global productivity by 1.5% annually and contribute to the creation of over 6 million new jobs. Positioning itself as a domestic solution to this global shift, First Phosphate is actively developing a vertically integrated North American LFP ecosystem—from mining to battery-grade materials. The company controls over 1,000 sq. km of high-purity igneous phosphate claims in Quebec, an area capable of supporting more than 350 GWh of LFP battery production each year. Its phosphate ore is among the cleanest in the world, naturally low in harmful elements and extractable without the use of solvents. This vertical integration strategy allows First Phosphate to manage the entire value chain, from resource extraction to the production of LFP cathode active material (CAM). The result: a fully traceable, secure, and sustainable domestic supply chain that supports the growing demands of North America’s electrified #proactiveinvestors

Futura Medical PLC CEO James Barder takes Proactive's Stephen Gunnion through the company’s 2024 financial performance, market expansion and product pipeline. Futura reported a strong year in 2024, with CEO Barder highlighting revenue of £14 million and a maiden profit of £1.3 million—or £3.3 million excluding non-cash items. Barder noted that Eroxon is now sold in over 15 countries and is expected to reach over 20 by the end of 2025. “2024 was a very good year for us,” he said. Barder emphasised the company’s commitment to supporting commercial partners and building momentum behind its flagship product, Eroxon. He explained that markets seeing the most success were those effectively targeting men under 60 with mild to moderate erectile dysfunction—Eroxon’s most responsive user group. The conversation also touched on upcoming products, including Eroxon Intense, a variant delivering a stronger sensory experience, and SD4000, a topical treatment for female sexual dysfunction. Barder noted that 87% of women in clinical trials for SD4000 wished to continue use post-study—an encouraging sign. Looking ahead, Barder said the company will continue expanding its presence, drive forward its pipeline, and focus on areas it can control, despite share price frustrations. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and hit the bell icon for updates. #FuturaMedical #Eroxon #EroxonIntense #SD4000 #ErectileDysfunction #FemaleHealth #PharmaNews #OTCProducts #HealthcareInnovation #BiotechUpdate

Solvonis Therapeutics PLC CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the proposed acquisition of Awakn Life Sciences following strong shareholder approval. Over 99% of Awakn’s shareholders voted in favour of the transaction, which Tennyson described as a “great endorsement” of the strategic fit and potential of combining the two companies. Solvonis is acquiring Awakn for around £5 million in an all-stock transaction. The deal includes two key clinical-stage programs. The lead candidate, AWKN-001, targets severe AUD in the UK and EU markets. It is currently in phase three trials. According to Tennyson, “People coming on to that trial were sober seven days a year. Those who went through the active arm... achieved on average 86% sobriety in the six months post-treatment.” PharmaVentures, which is advising on the deal, has suggested the asset could potentially deliver up to £60 million in milestone payments and generate double-digit royalties. A second program, AWKN-002, aimed at the US market, is in phase 2B planning and may yield up to £150 million in similar payments if successful. The acquisition is seen as a key step in establishing Solvonis as a UK-based biotech focused on addiction and mental health. Visit Proactive’s YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe to the channel and enable notifications for future content. #SolvonisTherapeutics #AwaknAcquisition #AlcoholUseDisorder #MentalHealthTreatment #BiotechInvesting #ClinicalTrials #AWKN001 #AddictionRecovery #PharmaVentures #InvestorNews